Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Boosted by Resolute Capital Asset Partners LLC

Resolute Capital Asset Partners LLC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 125.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 90,000 shares of the medical equipment provider's stock after purchasing an additional 50,000 shares during the quarter. Lantheus accounts for about 4.1% of Resolute Capital Asset Partners LLC's holdings, making the stock its 5th largest holding. Resolute Capital Asset Partners LLC owned 0.13% of Lantheus worth $7,226,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in Lantheus during the fourth quarter valued at $407,000. Principal Securities Inc. acquired a new stake in Lantheus in the 4th quarter worth about $28,000. Envestnet Portfolio Solutions Inc. boosted its holdings in Lantheus by 9.0% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,927 shares of the medical equipment provider's stock worth $305,000 after buying an additional 407 shares during the last quarter. Principal Financial Group Inc. increased its stake in Lantheus by 3.2% during the 4th quarter. Principal Financial Group Inc. now owns 291,465 shares of the medical equipment provider's stock worth $18,071,000 after buying an additional 9,128 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of Lantheus by 27.4% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 7,918 shares of the medical equipment provider's stock valued at $491,000 after acquiring an additional 1,701 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Trading Up 0.4 %

Shares of NASDAQ LNTH traded up $0.42 during trading on Thursday, reaching $108.56. The stock had a trading volume of 943,588 shares, compared to its average volume of 1,019,691. The business's 50-day moving average price is $106.08 and its 200-day moving average price is $83.62. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a market cap of $7.52 billion, a P/E ratio of 16.57 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same period in the previous year, the business posted $1.40 EPS. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gary J. Pruden sold 12,530 shares of the firm's stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now directly owns 11,978 shares in the company, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,852 shares of company stock worth $3,922,001. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of research reports. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Truist Financial cut their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. JMP Securities decreased their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Finally, B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.